GSK's $10.6 Billion Nuvalent Deal Raises Eyebrows -- Market Talk

Dow Jones

06/09

0906 GMT - The initial market reaction to GSK's $10.6 billion acquisition of cancer specialist Nuvalent points to some trepidation among investors about the size of the deal, AJ Bell's Russ Mould says. Nuvalent is the U.K. drugmaker's biggest acquisition in years and fits with its goal of turning oncology into a key growth engine for the group, Mould says. "GSK is paying a hefty premium to get the deal over the line and the two big lung cancer products flagged by [GSK CEO Luke] Miels in heralding the takeover still await regulatory approval," Mould says. "In rolling the dice on such a big transaction, he is undoubtedly taking a risk." GSK shares fall 3.3%. Nuvalent jumps 38% in U.S. premarket trading. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

June 09, 2026 05:07 ET (09:07 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2642465642"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2642465642\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2642465642?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-09 17:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642465642","market":"other","top_or_hot":-1,"title":"GSK's $10.6 Billion Nuvalent Deal Raises Eyebrows -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0906 GMT - The initial market reaction to GSK's $10.6 billion acquisition of cancer specialist Nuvalent points to some trepidation among investors about the size of the deal, AJ Bell's Russ Mould says. Nuvalent is the U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. drugmaker's biggest acquisition in years and fits with its goal of turning oncology into a key growth engine for the group, Mould says. \"GSK is paying a hefty premium to get the deal over the line and the two big lung cancer products flagged by [GSK CEO Luke] Miels in heralding the takeover still await regulatory approval,\" Mould says. \"In rolling the dice on such a big transaction, he is undoubtedly taking a risk.\" GSK shares fall 3.3%. Nuvalent jumps 38% in U.S. premarket trading. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 09, 2026 05:07 ET (09:07 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GSK's $10.6 Billion Nuvalent Deal Raises Eyebrows -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGSK's $10.6 Billion Nuvalent Deal Raises Eyebrows -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-09 17:07</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0906 GMT - The initial market reaction to GSK's $10.6 billion acquisition of cancer specialist Nuvalent points to some trepidation among investors about the size of the deal, AJ Bell's Russ Mould says. Nuvalent is the U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. drugmaker's biggest acquisition in years and fits with its goal of turning oncology into a key growth engine for the group, Mould says. \"GSK is paying a hefty premium to get the deal over the line and the two big lung cancer products flagged by [GSK CEO Luke] Miels in heralding the takeover still await regulatory approval,\" Mould says. \"In rolling the dice on such a big transaction, he is undoubtedly taking a risk.\" GSK shares fall 3.3%. Nuvalent jumps 38% in U.S. premarket trading. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 09, 2026 05:07 ET (09:07 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NUVL","symbol_name":"Nuvalent, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2642465642","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642465642","pubTimestamp":1780996020,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0906 GMT - The initial market reaction to GSK's $10.6 billion acquisition of cancer specialist Nuvalent points to some trepidation among investors about the size of the deal, AJ Bell's Russ Mould says. Nuvalent is the U.K. drugmaker's biggest acquisition in years and fits with its goal of turning oncology into a key growth engine for the group, Mould says. \"GSK is paying a hefty premium to get the deal over the line and the two big lung cancer products flagged by [GSK CEO Luke] Miels in heralding the takeover still await regulatory approval,\" Mould says. \"In rolling the dice on such a big transaction, he is undoubtedly taking a risk.\" GSK shares fall 3.3%. Nuvalent jumps 38% in U.S. premarket trading. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NUVL":"Nuvalent, Inc.","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4532":"文艺复兴科技持仓","BK4139":"生物科技","GSK":"葛兰素史克","GSK.UK":"葛兰素史克","LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4007":"制药","GSKH":"GSK plc ADRhedged","BK4539":"次新股"},"translate_title":"葛兰素史克(GSK)106亿美元的Nuvalent交易引发关注——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSKH":0.6,"NUVL":1.5,"GSK":1.5,"GSK.UK":0.6},"content_text":"0906 GMT - The initial market reaction to GSK's $10.6 billion acquisition of cancer specialist Nuvalent points to some trepidation among investors about the size of the deal, AJ Bell's Russ Mould says. Nuvalent is the U.K. drugmaker's biggest acquisition in years and fits with its goal of turning oncology into a key growth engine for the group, Mould says. \"GSK is paying a hefty premium to get the deal over the line and the two big lung cancer products flagged by [GSK CEO Luke] Miels in heralding the takeover still await regulatory approval,\" Mould says. \"In rolling the dice on such a big transaction, he is undoubtedly taking a risk.\" GSK shares fall 3.3%. Nuvalent jumps 38% in U.S. premarket trading. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 09, 2026 05:07 ET (09:07 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}